FindTrial
Sign In

Can CBD Help People Recover from Opioid Addiction?

Cannabidiol as an Adjunctive Therapy in Opioid Agonist Treatment for Patients with Opioid Dependence An Open-Label Study. - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/11/097181
Enrollment
70
Registered
2025-11-11
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F112- Opioid dependence

Interventions

Intervention1: OAT + Adjunctive Cannabidiol, Active: Group 1 receiving-800mg CBD + Buprenorphine (2mg) + T. Naloxone (0.5mg) as OAT at day1, day2 and day 3 and Final rating of scales on day 10. Co

Sponsors

Central Institute Of Psychiatry, Ranchi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with opioid dependence, current use (6C43.20) in ICD-11. Male and females Age : 18-60 year Ability to provide informed consent.

Exclusion criteria

Exclusion criteria: Patient dependent on any other psychoactive drugs other than nicotine and caffeine. Diagnosis of any Axis I psychiatric condition. Significant medical history or hypersensitivity to cannabinoids. Significant medical or neurological illness including severe cardiovascular, hepatic, renal, anaemia, history of severe head injury or myopathy or untreated thyroid disease. Not willing to give written informed consent.

Design outcomes

Primary

MeasureTime frame
To compare the reduction in opioid craving in patients with opioid dependence at baseline, after first between the patients receiving adjunctive CBD and T. Buprenorphine (2mg) + T. Naloxone (0.5mg) as OAT (Opioid Agonist Therapy), Vs patents receiving T. Buprenorphine (2mg) + T. Naloxone (0.5mg).Timepoint: primary outcomes are assessed at baseline, day1 ,day2,day3,and on day10—

Secondary

MeasureTime frame
To compare the decline in opioid withdrawal symptoms manifested in patients with opioid dependence at baseline, post first dose (day 1), second dose (day 2), and third dose (day 3) of CBD and on day 10 among patients receiving adjunctive CBD and T. Buprenorphine 2mg + T. Naloxone (0.5mg) as OAT (Opioid Agonist Therapy), Vs patents receiving T. Buprenorphine (2mg) + T. Naloxone (0.5mg).Timepoint: secondary outcomes are assessed at baseline, day1 ,day2,day3,and on day10—

Countries

India

Contacts

Public ContactDr Alok Pratap

Central Institute of Psychiatry, Ranchi

dralokpratap@gmail.com7781803812

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026